1.
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
by van der Graaf, Winette TA, Prof
The Lancet (British edition), 2012, Vol.379 (9829), p.1879-1886
2.
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
by Robert, Caroline, Prof
The Lancet (British edition), 2014, Vol.384 (9948), p.1109-1117
3.
Cutaneous melanoma
by Eggermont, Alexander MM, Prof
The Lancet (British edition), 2014, Vol.383 (9919), p.816-827
4.
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
by Falchook, Gerald S, Dr
The Lancet (British edition), 2012, Vol.379 (9829), p.1893-1901
5.
International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women
by Lortet-Tieulent, J
Lung cancer (Amsterdam, Netherlands), 2014, Vol.84 (1), p.13-22
6.
The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination
by Wallach, David
Nature, 2003-08-14, Vol.424 (6950), p.801-805
7.
CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members
by Mosialos, George
Nature, 2003-08-14, Vol.424 (6950), p.793-796
8.
Non-melanoma skin cancer
by Madan, Vishal, MRCP
The Lancet (British edition), 2010, Vol.375 (9715), p.673-685
9.
Identification of cells initiating human melanomas
by Frank, Markus H
Nature, 2008-01-17, Vol.451 (7176), p.345-349
10.
Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling
by MALANCHI, Ilaria
Nature (London), 2008, Vol.452 (7187), p.650-653
11.
Genetic alterations defining NSCLC subtypes and their therapeutic implications
by Pikor, Larissa A
Lung cancer (Amsterdam, Netherlands), 2013, Vol.82 (2), p.179-189
12.
BRAFE600-associated senescence-like cell cycle arrest of human naevi
by MICHALOGLOU, Chrysiis
Nature (London), 2005, Vol.436 (7051), p.720-724
13.
NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia
by Khavari, Paul A
Nature (London), 2003-02-06, Vol.421 (6923), p.639-643
14.
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
by Getz, Gad
Nature, 2005-07-07, Vol.436 (7047), p.117-122
15.
BHD mutations, clinical and molecular genetic investigations of Birt–Hogg–Dubé syndrome: a new series of 50 families and a review of published reports
by Toro, J R
Journal of Medical Genetics, 2008-06, Vol.45 (6), p.321-129
16.
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial
by Gillgren, Peter, Dr
The Lancet (British edition), 2011, Vol.378 (9803), p.1635-1642
17.
Malignant melanoma in the 21st century, Part 1: Epidemiology, risk factors, screening, prevention, and diagnosis
by MARKOVIC, Svetomir N
Mayo Clinic proceedings, 2007, Vol.82 (3), p.364-380
18.
Toxicity and Carcinogenicity of Chromium Compounds in Humans
by Costa, Max
Critical reviews in toxicology, 2006, Vol.36 (2), p.155-163
19.
Increasing Incidence of Melanoma Among Young Adults: An Epidemiological Study in Olmsted County, Minnesota
by Reed, Kurtis B., MD
Mayo Clinic proceedings, 2012, Vol.87 (4), p.328-334
